On Nov. 9, Merck & Co., after long insisting it would never settle the 27,000 Vioxx cases filed against it, turned an about face and agreed to a global settlement in which it will pay $4.85 billion to resolve the bulk of these cases. Two of the lawyers who were instrumental in bringing this about join us to discuss the settlement on the latest episode of the legal-affairs podcast Lawyer2Lawyer. My cohost J. Craig Williams and I discuss the terms of the settlement and its implications with:

We invited representatives of Merck and also of the Defense Research Institute to appear on the program, but they declined.

Listen to or download the show from this page. Subscribe to future episodes of Lawyer2Lawyer usings its RSS feed or subscribe via iTunes.

  • Anonymous

    If you’re a plaintiff in the Vioxx litigation and have questions or
    concerns about the recent settlement offer, visit our group. The group
    was started by a plaintiff for the sole use of plaintiffs to exchange
    information. Tell your story or just observe. If you’re not a
    plaintiff, but know someone who is, please pass this information along.